Comparing Tablet Minoxidil And Tablet Finasteride In The Treatment of Male Pattern Baldness

Phase 4

• Conditions: Health Condition 1: L649- Androgenic alopecia, unspecified

• Registration Number: CTRI/2023/08/056334
• Lead Sponsor: Rithvik Mudalakatte Hegde

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 August 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Patients with clinical features of Androgenetic Alopecia in the age group of 18 years to 50 years presenting in the Department of Dermatology Venerology and Leprosy, of A.J Institute of Medical Science, Mangalore.

2. Patients with clinical features of Androgenetic Alopecia of grades II to V according to the Norwood-Hamilton scale presenting in the Department of Dermatology Venerology and Leprosy, of A.J Institute of Medical Science, Mangalore.

3. Have Androgenetic Alopecia that in the opinion of the healthcare professional is suitable for treatment with both low dose oral minoxidil and oral finasteride.

Exclusion Criteria

1. Patients who are using and/or continuing other treatment modalities for androgenetic alopecia.

2. Patients who have abnormal blood pressure (BP), I.e. Systolic BP < 90 or > 180 mmHg and Diastolic BP <60 or > 120 mmHg.

3. Patients having abnormal liver function test.

4. Patients having a history of abnormal thyroid conditions.

5. Any unstable serious co-existing medical conditions.

6. Patients with a history or current evidence of any serious and/or unstable pre-existing medical or psychiatric disorder.

7. Patients diagnosed with pheochromocytoma.

8. Patients having any history of heart conditions or any abnormal cardiac examination findings.

9. Patients with a history of allergy to oral minoxidil/finasteride or its components.

10. Patients with a history of use of light or laser treatment of scalp.

11. Patients with a history of use of minoxidil (oral/topical) within 12 months.

12. Patients with a history of use of Dutasteride/ finasteride within 12 months.

13. History of receiving chemotherapy within 12 months.

14. Having a scalp skin disease at the area of treatment.

15. Patients with a history of use of systemic steroids (i.e. prednisone, methylprednisolone, etc) for at least 2 weeks within 3 months

16. Patients with a history of use of drugs that will affect hair growth such as carpronium chloride, anti-androgenic drugs (cyproterone acetate, spironolactone, ketoconazole, flutamide and bicalutamide), ketoconazole shampoo, estrogen, progesterone, prostaglandin analogs, tamoxifen, drugs induced hypertrichosis (cyclosporine diazoxide, phenytoin, psoralens) drugs induced hypotrichosis/ telogen effluvium (valproic acid, anabolic steroids, lithium and phenothiazines)

17. Patients who are unable to give informed consent.

18. Non-compliant patients.

Study & Design

• Study Type: PMS
• Study Design: Not specified